Pharmaceutical Benefit-Risk Perception and Older Age:A Pilot Study by Balog-Way, Dominic & Lofstedt, Ragnar Ernst Vilhelm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Balog-Way, D., & Lofstedt, R. E. V. (Accepted/In press). Pharmaceutical Benefit-Risk Perception and Older Age:
A Pilot Study . Therapeutic innovation & regulatory science.
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 12. Sep. 2019
For Peer Review
Pharmaceutical Benefit-Risk Perception and Older Age: A 
Pilot Study 
Journal: Therapeutic Innovation & Regulatory Science
Manuscript ID TIRS-19-0078
Manuscript Type: Original Articles
Date Submitted by the 
Author: 10-May-2019
Complete List of Authors: Balog-Way, Dominic; Cornell University, ; King's College London,  King's 
Centre for Risk Management
Lofstedt, Ragnar; Kings College, 
Keywords: Older age, Benefit-risk perception, Affect, Pharmaceuticals
Abstract:
Background: Older age plays an important role in pharmaceutical 
benefit-risk perception. This creates challenges and opportunities, 
especially for regulatory authorities and advocacy groups seeking to 
communicate with patients of all ages. This study explored the 
pharmaceutical benefit-risk perceptions of older versus younger adults to 
identify age-related effects for further study. Methods: 80 face-to-face 
surveys were conducted with samples of older and younger respondents 
from Boulder, Colorado (USA) and Dublin (Ireland). Results: Older adults 
were more likely than their younger counterparts to view greater risk 
today than twenty years ago for 13/15 items ranging from diabetes and 
Alzheimer’s disease, to patients taking prescription medicines. Both older 
and younger respondents perceived most medical treatments as high in 
benefit and low in risk. Older adults construed ‘risk’ variably as (1) side 
effects, (2) dangers of inappropriate use and (3) wider issues. Crucially, 
older adults’ quantitative benefit-risk judgements were strongly 
influenced by personal experiences and the positive/negative feelings 
they most associated with different medicines, medical procedures and 
tests. While positive associations influenced high benefit perceptions, 
negative associations influenced high risk perceptions. Conclusion: Age-
related effects on risk perception should be further explored to help 
improve the effectiveness of benefit-risk communication for adults of all 
ages.
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Pharmaceutical Benefit-Risk Perception and Older Age: A Pilot Study 
Abstract
Background: Older age plays an important role in pharmaceutical benefit-risk perception. This 
creates challenges and opportunities, especially for regulatory authorities and advocacy groups 
seeking to communicate with patients of all ages. This study explored the pharmaceutical 
benefit-risk perceptions of older versus younger adults to identify age-related effects for further 
study. Methods: 80 face-to-face surveys were conducted with samples of older and younger 
respondents from Boulder, Colorado (USA) and Dublin (Ireland). Results: Older adults were 
more likely than their younger counterparts to view greater risk today than twenty years ago 
for 13/15 items ranging from diabetes and Alzheimer’s disease, to patients taking prescription 
medicines. Both older and younger respondents perceived most medical treatments as high in 
benefit and low in risk. Older adults construed ‘risk’ variably as (1) side effects, (2) dangers of 
inappropriate use and (3) wider issues. Crucially, older adults’ quantitative benefit-risk 
judgements were strongly influenced by personal experiences and the positive/negative 
feelings they most associated with different medicines, medical procedures and tests. While 
positive associations influenced high benefit perceptions, negative associations influenced high 
risk perceptions. Conclusion: Age-related effects on risk perception should be further explored 
to help improve the effectiveness of benefit-risk communication for adults of all ages. 
Keywords: older age, benefit-risk perception, pharmaceuticals, affect
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(1.) Background
Understanding how patients perceive the benefits and risks of medicines is a “pre-requisite” 
for effective pharmaceutical benefit-risk communication.1 Risk perception knowledge can be 
used to correct patient misconceptions, strengthen accurate beliefs and add missing information 
that is ‘material’ to decision-making.2-4 Interventions informed by perception research can 
close the gap between what patients know and what they need to know.5 Communicators such 
as regulatory authorities, including the European Medicines Agency and the US Food and Drug 
Administration, and patient advocacy groups can more effectively achieve their 
communication goals.6-10 Utilising risk perception knowledge ultimately contributes to 
ensuring medicines are used safely and effectively. 
Benefit-risk perception research has evolved significantly,1,5,6,11 however; only a small corpus 
of work has investigated the role of older age as a central focus of study.12 One issue is that 
few psychological judgement and decision-making studies on ageing have been conducted in 
applied pharmaceutical contexts.12 Since the US National Research Council published two 
influential reports13,14 in the 2000s, psychological research on ageing has advanced 
substantially (see Hess et al.15). However, studies have focused more on basic neurobiological 
and behavioural mechanisms than understanding “the specific contexts in which older adults 
function” (p6).16 This has limited scholars to suggesting ways that findings from non-risk 
contexts are likely to be important for benefit-risk communication.17-19 Bruine de Bruin19, for 
instance, explained how findings on age-related changes in cognitive deliberation, experience-
based knowledge, emotions and motivation might inform interventions such as decision aids, 
training, delegation and ‘nudge-based’ approaches. While these suggestions are constructive, 
pharmaceutical benefit-risk communication tools would be better informed by more 
contextually-relevant risk perception knowledge. 
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A second issue is that few risk perception studies have investigated the role of age as a central 
focus of study. Early risk perception studies were frequently limited to younger student 
populations. More recently, thousands of studies have collected risk perception data and either 
not reported age-related results, or presented age as a confounder of a stronger relationship 
with another variable such as gender, risk beliefs or trust.20 Rather than focusing on (older) 
age, researchers have been more interested in the characteristics of hazards (dread, uncertainty, 
controllability), or other characteristics of perceivers (gender, race, socio-economic status).21-
26 
There is now considerable evidence that older age must be investigated more carefully, 
critically and extensively.15-20 Not least because, in the pharmaceutical context, most older 
adults use prescription and over-the-counter medicines, older adults consume the highest 
percentage of medicines by age group, and, to compound these factors, virtually every country 
in the world is experiencing growth in the number and proportion of older persons.27-29 In 
addition, more responsibility has shifted to adults of all ages with trends towards empowering 
patients through shared decision-making, informed choice and the right to challenge 
physicians.30-32 
This pilot study explored the role of older age in pharmaceutical benefit-risk perception. The 
primary goal was to generate experimental evidence to inform future pharmaceutical benefit-
risk perception research on age-related effects across the adult life span. The two main research 
objectives were to (1) compare older versus younger adults’ pharmaceutical benefit-risk 
perceptions and identify clear age-related differences; and (2) explore qualitatively how older 
Page 3 of 42
http://mc.manuscriptcentral.com/tirs
Therapeutic Innovation & Regulatory Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
4
adults make quantitative judgements about the benefits and risks of various medicines, medical 
procedures, and tests.
(2.) Methods
A questionnaire, modelled on nationally representative surveys conducted in Sweden, Canada, 
and the US by Paul Slovic and colleagues,1,33,34 was developed in 2017. A key difference 
between the present study and those by Slovic et al. was the addition of various open-ended 
questions. This generated extensive qualitative data on why respondents gave their benefit-risk 
judgements. The initial questionnaire was piloted face-to-face with a convenience sample of 
five respondents aged over 55 years old from London (UK) or Boulder, Colorado (USA). This 
informed three main changes: a slideshow visual aid was added to assist respondents in 
understanding survey questions; the questionnaire was shortened substantially; and minor 
wording changes were made. The study was approved by King College London’s Research 
Ethics Office (MR/17/18-278).
(2.1) Sample
A total of 80 respondents were recruited from Boulder County, Colorado (USA) and Dublin 
(Ireland) (hereafter, Boulder and Dublin). Respondents were recruited through convenience 
sampling using online adverts and by approaching members of the public in cafés, public 
libraries and quiet hotel lobbies, as well snowball sampling through the interviewers’ private 
networks. Demographic data was collected for both samples on age, sex, education and 
employment (Table 1). Data was also collected on two general indicators of health behaviour: 
whether respondents (1) currently have a doctor and (2) smoke cigarettes. 
Table 1: Demographic and health information for older and younger samples
Older Sample Younger Sample
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Dates Nov. 1st – 10th, 2017 Feb 1st – 14th, 2018
Sample size 40 40
Age Range 58 to 93 31 to 50
Mean Age 72 39
Male 44% 45%
Education (%) Some schooling complete/ No high school diploma 23% 0%
High School Graduate or 
Equivalent 18% 30%
Bachelor’s Degree 21% 50%
Master’s Degree 36% 20%
Professional/ Doctorate 
Degree 3% 0%
Employment (%) Working Full-Time 13% 45%
Working Part-Time 23% 25%
Retired 64% 3%
Full Time Homemaker 0% 5%
Unemployed (looking for 
work) 0% 8%
Student 0% 10%
Other 0% 5%
Do you currently 
have a doctor? 
(%)
Yes 97% 60%
Do you currently 
smoke? (%) Yes 0% 35%
Older Group. The older sample had 40 respondents from Boulder (N=20) and Dublin (N=20). 
They had a mean age of 72, their ages ranged from 58 to 93, and 44% were male. The large 
majority (87%) were either retired (64%) or working part-time (23%) and only 13% were 
working full-time. 60% had a bachelor’s degree or higher, while 23% had only some schooling/ 
no high school diploma. None smoked and 97% had a doctor.
Younger Group. The younger sample had 40 respondents from Boulder (N=20) and Dublin 
(N=20). They had a mean age of 39, their ages ranged from 31 to 50 and 45% were male. The 
large majority (80%) were either working full-time (45%), working part-time (25%), or 
students (10%). 70% had a bachelor’s degree or higher, and all younger group respondents had 
graduated from high school or equivalent. 35% smoked and 60% had a doctor. 
(2.2) Survey administration
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Surveys were conducted in November 2017 (older sample) and February 2018 (younger 
sample). They were administered face-to-face by the lead author and 3 trained research 
assistants. Face-to-face interviewing generated in-depth qualitative data. 78/80 survey 
interviews were audio recorded and transcribed1.
Part 1: Words associated to prescription medicines. 
Respondents were asked to indicate the first thought or association that comes to mind when 
reading the words “Prescription Medicines”. The stimulus was shown on a laptop and not read 
aloud. The question was repeated twice more2. This continued associations technique is “a 
sensitive indicator of the imagery and meaning associated with people’s mental representations 
for a wide variety of concepts” (p82).1
Part 2: General questions on medicines and other technologies
Perceptions of how risks have changed over time. Respondents were asked whether they 
believe there is more risk, less risk or about the same risk today than there was 20 years ago 
from sixteen separate items (Table 2). Similar questions about how risks have changed over 
time were included in past surveys examining risks to life generally (e.g. Harris35) and for a 
variety of specific hazards (e.g. Slovic et al.1,21). The sixteen items are hazards with a variety 
of characteristics (dread potential, familiarity, control, voluntariness) and are managed in 
differing policy contexts (healthcare, energy, pharmaceuticals, health and safety). Some items 
were selected from past studies, others were unique to this study. 
1 Two respondents consented to be interviewed but did not consent to being audio recorded. 
2 When piloting the present survey face-to-face it quickly became clear that respondents struggled to make more 
than 3 associations.
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Table 2: Sixteen hazard items
Air travel Heart disease
Adults getting Alzheimer’s disease Hurricanes
Cancer Adults getting HIV/AIDS
Climate change Nuclear power
Diabetes Pesticides
Driving a car Adults taking prescription medicines
Doctors making prescribing errors Train travel
Flooding Chemicals
Performance of key actors. Respondents were asked to rate the performance of doctors, 
pharmacists, pharmaceutical regulatory agencies, pharmaceutical companies, and patients in 
making sure that prescription medicines are safe and effective. The ordering of each actor was 
randomised between respondents. 
Experiences with and perceptions of side effects. Respondents were asked about their personal 
experiences with prescription medicine side effects. This included (1) how often they believe 
that medicines work as intended for patients, (2) how often they believe patients experience 
unwanted side effects, and (3) whether they have (knowingly) had a mild, moderate or severe 
side effect over the past five years. 8 further questions indicated what respondents perceive to 
be the causes of side effects including patients being unusually sensitive to medicines, patient 
not following instructions, and doctors prescribing the wrong dosage.
Part 3: Psychometric benefit and risk questions
Over the past 50 years, different approaches to measuring perceived benefit and perceived risk 
have evolved. In psychometric studies, respondents are asked to make quantitative judgements 
about the risks of various hazards and technologies. They provide a well-established and 
reliable method for measuring respondents’ perceptions of benefit and risk quantitively. The 
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advantages and limitations of the psychometric paradigm have been discussed at length 
elsewhere.36-39
In the present study, numeric scaling methods were used. Respondents were asked to rate the 
risks and benefits of 27 medical and non-medical technologies and hazards on a scale of 1 to 7 
(Box 1). Two questions were asked on benefits and risks of 17 medical technologies (i.e. 
medical treatments), and two further and almost identical questions on 10 non-medical 
technologies. The items were 14 prescription and over-the-counter medicines, 2 medical 
procedures, 2 medical tests, and 10 non-medical technologies (Table 3). Including questions 
that independently measure specific dimensions of risk perception – such as actual probability 
of experiencing harm, the severity of the consequences of that result, or affective components40 
– were intentionally excluded. Instead, by asking general risk perception questions, the authors 
could explore how respondents construed the ‘risks’ and ‘benefits’ themselves, as well as the 
different ways that older adults justify quantitative benefit-risk judgements. 
Box 1: Psychometric risk and benefit questions
Risks of medical technologies (to those exposed). To what extent would you say that adults who are taking or 
undergoing this medical treatment are at risk3 of experiencing personal harm from it? (1 = they are not at risk; 
7 = they are very much at risk)
Benefits of medical technologies. In general, how beneficial do you consider this treatment to be? (1 = not at 
all beneficial; 7 = very beneficial)
Risks of non-medical technologies (to those exposed). To what extent would you say that adults who are 
exposed to the following are at risk2 of experiencing personal harm from it? (1 = they are not at risk; 7 = they 
are very much at risk)
Benefits of non-medical technologies. In general, how beneficial do you consider the following items to be for 
those exposed to it? (1 = not at all beneficial; 7 = very beneficial)
After rating each technology from 1 to 7, respondents were asked why they gave their answer. 
The closed questions (quantitative measures) provided a platform for investigating the reasons 
behind respondents’ benefit and risk perceptions (qualitative measures). Asking follow-up 
3 ‘Risk’ was intentionally not defined. Respondents were left to interpret what ‘risk’ meant for each technology.  
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questions for a total of 54 questions (27 items x 2 questions each), would have made the 
questionnaire too long leading to survey fatigue. Therefore, trained interviewers asked follow-
up questions when it seemed appropriate to them. 
Table 3: Medical and non-medical items surveyed
Medicines Medical Procedures & Tests Non-Medical Technologies
Medicine to treat depression Heart surgery Cell phones
Medicines to slow the progression 
of Alzheimer’s disease
Medical x-rays Nuclear power plants
Medicines to treat erectile 
dysfunction
Prostate screening tests Pesticides
Antibiotics Acupuncture Cigarette smoking
Sleeping pills High-fat foods
Herbal medicines Genetically modified food
Cancer chemotherapy Automobiles
Insulin Alcoholic beverages
Medicines for cholesterol (e.g. 
statins)
Coffee
Vitamin pills Air travel
Blood pressure medicines
MMR vaccine
Flu vaccine
Allergy medicines
 (3.) Results
(3.1) Associations to Prescription Medicines
Respondents gave a total of 187 spontaneous associations to the term ‘Prescription Medicines’. 
Although 3 associations were requested, many struggled to give more than 2 resulting in a 
mean average of 2.3 per respondent. Qualitative content analyses revealed 12 broad categories 
of associations (Table 4). The three most frequently associated images were of health care 
professionals (e.g. prescribing doctors or pharmacists) (15% of all associations), the benefits 
of medicines (e.g. medicines are helpful, beneficial or good) (11%), and types of disease or 
illness (11%). Other frequent images were of dependency, abuse, and over-prescribing (10%), 
names of specific drugs (9%), and side effects in general (7%).
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Almost a quarter (24%) of all older group associations were to the benefits of medicines, 
compared to only 7% in the younger group. Concerns about expense were much higher in the 
older (10%) versus younger (2%) group. Only 5% of all older group associations were to 
images of dependency, abuse and over-prescribing. In contrast, this category was the second 
most common association in the younger group (15%) after general images of healthcare 
professionals (16%) and before types of disease and illness (11%). 
Table 4: Spontaneous imagery associated to “Prescription Medicines”
Older (%) Younger (%) All (%)
Helpful/Beneficial/Good 24 7 11
HCPs (e.g. "My Doctor") 14 16 15
Types of Disease and Illness 12 11 11
Expensive 10 2 6
Names of Specific Drugs 9 9 9
Side Effects 8 7 7
Own and Family Prescription Medicines 6 3 5
Dependency/Abuse/Over-Prescribing 5 15 10
Annoying/Want to Avoid if Possible 4 5 5
Industry Profits 2 4 3
General Safety 1 5 3
Other (e.g. Packaging) 7 15 14
No. of Responses 93 (count) 94 (count) 187 (count)
(3.2) Perceptions of How Risks have Changed Over Time
Respondents were asked whether they believe there is more risk, less risk or about the same 
risk today than there was 20 years ago from 16 items (Table 5). For 11/15 items over 50% of 
all respondents indicated greater perceived risk. The largest proportion of respondents 
believing there is ‘more’ risk was for climate change (94%), diabetes (78%), flooding (76%) 
and adults taking prescription medicines (74%). This was followed by hurricanes (71%), cancer 
(69%), chemicals (69%), adults getting Alzheimer’s disease (65%), heart disease (65%), 
pesticides (63%), driving a car (53%), and nuclear power (50%). Fewer than half of 
respondents indicated greater perceived risk from doctors making prescribing errors (48%), 
adults getting HIV (35%), air travel (34%), and train travel (19%). A large percentage of 
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respondents indicated that they believe there is less risk today than 20 years ago for adults 
getting HIV (53%), air travel (50%), and train travel (46%). Fewer than 30% of all respondents 
indicated less risk for all 13 other items.
Older versus younger respondents were more likely to indicate higher perceived risk than 20 
years ago for 14 out of 16 items. Over 20% more older respondents indicated greater perceived 
risk from chemicals (+23% older respondents indicating ‘more’ risk), flooding (+23%), and 
hurricanes (+23%). This was followed by adults getting HIV (+20%), doctors making 
prescribing errors (+20%), and train travel (+18%). Heart disease (-13% older respondents 
indicating ‘more’ risk) and cancer (-5%) were the only two items that fewer respondents from 
the older versus younger group perceived as riskier than 20 years ago.
Table 5: Percentage of all respondents (N=80) for the question: ‘Do you think there is more, less, or about the 
same risk today than 20 years ago for the following items?’ 
More Less About the Same
Climate Change 94 3 4
Diabetes 78 11 11
Flooding 76 6 18
Adults Taking Prescription Medicines 74 13 14
Hurricanes 71 4 25
Cancer 69 11 19
Chemicals 69 16 15
Adults Getting Alzheimer’s Disease 65 8 26
Heart Disease 65 11 24
Pesticides 63 24 14
Driving a Car 53 29 19
Nuclear Power 50 23 28
Doctors Making Prescription Errors 48 21 30
Adults Getting HIV 35 53 10
Air Travel 34 50 16
Train Travel 19 46 35
 (3.3) Ensuring Medicines are Safe and Effective
Respondents were asked to rate the job of five separate actors in making sure that prescription 
medicines are safe and effective (Table 6). Three quarters (75%) rated pharmacists as either 
Page 11 of 42
http://mc.manuscriptcentral.com/tirs
Therapeutic Innovation & Regulatory Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
12
excellent (29%) or good (45%) in ensuring that medicines are safe and effective. Lower ratings 
were given to doctors (55% excellent or good), pharmaceutical companies (45%) and 
regulatory agencies (43%). At the bottom of the list, fewer than a third (28%) of respondents 
rated patients (taking Rx) as either excellent (4%) or good (24%) in making sure they are safe 
and effective; two-thirds (69%) rated patients as either doing a fair (35%) or poor (34%) job.
Older versus younger group respondents were much more likely to rate prescribing doctors as 
excellent or good in making sure that prescription medicines are safe and effective (73% versus 
38%; +35% difference). Older versus younger respondents were also marginally more likely 
to rate all other actors are excellent or good by +10% for all four actors. 
Table 6: Table showing the percentage (%) of older and younger group respondents that rated five actors as either 
excellent or good in making sure that prescription medicines are safe and effective. 
Older (%) Younger (%) All (%)
Pharmacists 80 70 75
Prescribing Doctors 73 38 55
Pharma Companies 50 40 45
Regulatory Agencies 48 38 43
Patients 33 23 28
 (3.4) Effectiveness and Side Effects
Respondents were asked three related questions on the effectiveness and side effects of 
prescription medicines. First, the very large majority of all respondents believe that prescription 
medicines work at least often for patients (88% always, very often, often) (Table 7). All older 
group respondents (100%) indicated that prescription medicines are effective very often (43%) 
or often (58%). While most younger group respondents also indicated that prescription 
medicines are effective at least often (78% always, very often, often), slightly fewer than a 
quarter said that only occasionally work (23%). No respondents indicated that prescription 
medicines are rarely or never effective. 
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Second, the results show that 61% of respondents perceive that patients experience unwanted 
effects or side effects from prescription medicines at least often (Table 7). A concomitant 
proportion perceive that side effects occur only occasionally (31%) or rarely (8%). Little 
variation was found between older versus younger groups perception of unwanted effects of 
side effects occur . No respondents believed that unwanted effects or side effects occur never. 
Table 7: Respondents perceptions of effectiveness and side effects. Effectiveness: “How often do you believe that 
prescription medicines work as intended for patients?” Side Effects: “How often do you believe that patients 
experience unwanted effects or side effects from prescription medicines?” 
Effectiveness Side Effects
Older (%) Younger (%) All (%) Older (%) Younger (%) All (%)
Always 0 3 1 3 10 6
Very Often 43 20 31 20 18 19
Often 58 55 56 43 30 36
Occasionally 0 23 11 30 33 31
Rarely or Never 0 0 0 5 10 8
Third, 60% of respondents said they have had a side effect from taking a prescription medicine 
over the past five years with 24% of all respondents indicating they have had a severe side 
effect, 22% indicating a moderate side effect and 14% indicting only mild side effects. A 
greater number of older versus younger respondents indicated they have experienced side 
effects over the past five years (+14% older respondents indicating ‘yes’). 
Respondents were asked how often they think side effects from prescription medicines are 
caused by eight different explanations (Figure 1). The three most frequently perceived causes 
of side effects all related to patients. A large number of respondents perceived that patients not 
following instructions (58%), patients having insufficient information (49%) and patients being 
unusually sensitive to the prescription medicine (44%) are always, very often, or often a cause 
of side effects. This was followed by the patient’s health plan restricting access to safer 
medicine (38% always, very often, or often a cause), a lack of government regulation (24%) 
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and the doctor prescribing the wrong dosage (16%). Few respondents indicated that the cause 
of a side effect is due to hospitals or pharmacists making mistakes (11% and 9%, respectively, 
rating always, very often, or often)
0% 20% 40% 60% 80% 100%
Wrongly filled by pharmacist
Hospital mistake when filling prescription
Doctor prescribed wrong dosage
Lack of government regulating medicine
Patient health plan restricted access to safer medicine
Patient unusually sensitive to the medicine
Insufficient information to patient
Patient did not follow instructions
Always, Very Often, Often Occasionally Rarely Never
Figure 1: Bar chart showing how often all respondents (N=80) think side effects are caused by various 
explanations.
For both older and younger respondents, patients not following instructions, having insufficient 
information and being unusually sensitive to medicines were the three most frequently 
perceived causes of a side effect. The largest number of respondents (58%) in both the older 
and younger groups perceived patient not following instructions as the always, very often, or 
often the cause of a side effect. However, older versus younger respondents were more likely 
to perceive that hospital (+8% always, very often, often) and pharmacist (8%) mistakes as well 
as patient health plans restricting access to safer medicines (5%) are the cause of side effects. 
Older versus younger respondents were also less likely to perceive four other factors as being 
the cause of side effects: government regulation (-23% always, very often, or often), doctors 
prescribing the wrong dosage (-13%), patients being unusually sensitive to the medicine (-8%) 
and patients having insufficient information (-3%). 
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(3.7) Perceptions of Benefit and Risk
The geometric mean was calculated for respondents’ risk ratings for all 27 medical and non-
medical technologies (Figure 2). On the scale of 7 (they are very much at risk) to 1 (they are 
not at risk), the mean rating of perceived risk ranged from 6.35 (cigarette smoking) to 1.51 
(acupuncture) (Figure X). The five technologies with the highest perceived risk were cigarette 
smoking, pesticides, nuclear power plants, high fat foods and alcoholic beverages. Four other 
technologies had a perceived risk of over 4.0: cancer chemotherapy, sleeping pills, heart 
surgery and automobiles. Acupuncture, prostate screening tests, vitamin pills, and coffee were 
perceived as having the lowest risk of experiencing personal harm from the technology. 
The geometric mean was calculated for respondents’ benefit ratings for all 27 medical and non-
medical technologies (Figure 2). On the scale of 7 (very beneficial) to 1 (not at all beneficial), 
the mean rating of perceived benefit ranged from 6.00 (insulin) to 1.16 (cigarette smoking). 
The five technologies with the highest perceived benefit were insulin, medical X-rays, heart 
surgery, prostate screening tests and air travel. A further 10 technologies received a mean 
benefit rating of over 4.0. Cigarette smoking, high-fat foods, pesticides, genetically modified 
food (GMF), alcoholic beverages and nuclear power plants were perceived as having the lowest 
benefits with all six technologies receiving a mean rating of less than 3.0. 
Differences between older versus younger respondents’ risk and benefit perceptions were 
calculated by subtracting younger respondents mean risk and benefit ratings from older 
respondents mean risk and benefit ratings, respectively. For 21/27 technologies surveyed, older 
respondents had lower perceived risk than younger group respondents. Medicines to treat 
depression (-1.36 mean risk difference), genetically modified food (-1.13), and sleeping pills 
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(-1.01) topped the list of technologies that older respondents perceived as having less risk, 
which was closely followed by cancer chemotherapy (-0.91) and medicines to treat 
Alzheimer’s Disease (-0.88). At the other end of the list, herbal medicines (0.87), cigarette 
smoking (0.51) and vitamin pills (0.23) were perceived as riskier by older respondents. Older 
versus younger respondents perceived less benefit for 16 out of 27 technologies. Herbal 
medicines (-1.54 mean benefit difference), medicines to treat Alzheimer’s disease (-1.40), 
allergy medicines (-1.40) and prostate screening tests topped the list of technologies that older 
versus younger respondents perceived as having less benefit. This was followed by vitamin 
pills (-1.01), coffee (0.79) and heart surgery (-0.68). At the other end of the list, genetically 
modified food (0.96), pesticides (0.73) and cell phones (0.44) were perceived as more 
beneficial by older versus younger respondents. 
The mean risk and mean benefit ratings were plotted onto a factor space (Figure 3). The plot 
quickly shows that all of the items clustered into one of four quadrants. Most medical 
technologies (11 out of 18) were perceived as high in benefit and low in risk (top-left quadrant). 
Cell phones and air travel were also perceived as high in benefit and low in risk. Heart surgery, 
automobiles, and cancer chemotherapy were perceived as high in benefit but also high in risk 
(top-right quadrant). Vitamin pills, coffee, herbal medicines and medicines for treating 
Alzheimer’s Disease clustered together as technologies with low benefit and low risk (bottom 
left quadrant). Sleeping pills was the only medical technology that was perceived as being low 
in benefit and high in risk (bottom right quadrant). In contrast six non-medical technologies 
clustered into the low benefit and high-risk quadrant.
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Figure 2: 
(A) Mean Risk
(B) Mean Benefit
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Figure 3: Plot of Benefit and Risk Means.  GMF:  Genetically Modified Food ED: Erectile Dysfunction AD: Alzheimer’s Disease [High resolution image submitted separately]. 
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 (3.8) Justifications for Risk and Benefit Ratings
Older respondents were asked ‘Why?’ they gave their risk and benefit ratings for some but not 
all pharmaceutical items. A total of 276 open-ended responses were recorded and transcribed 
with an average of 8/34 open-ended follow-up questions per older group respondent. The 
authors coded and categorised responses using a qualitative content analysis.41 The analysis 
revealed two main ways that respondents justified their risk and benefit ratings for 
pharmaceutical items: (1) describing risks and benefits, and (2) conveying experiences and 
feelings associated with each item.
Describing risks and benefits. The first main way that respondents justified their ratings was 
by simply describing the ‘risks’ and ‘benefits’ that they associated with different items  (Table 
8). 
Table 8: Older respondents’ (N=40) most common risk and benefit associations for all pharmaceutical items.
Item Risks Benefits
Medicines to treat 
depression
Suicide; over-dose; 
incorrect use
Benefits vary between 
patients; Patients need 
appropriate medicines 
Medicines to treat 
Alzheimer’s Disease
Low knowledge of any 
risks
Low knowledge of any 
benefits
Medicines to treat erectile 
dysfunction
Most unaware of any risks; 
Prolonged erections 
Very effective for those 
who need them
Antibiotics Antimicrobial resistance 
and over-use
Antimicrobial 
resistance reduces 
benefits
Sleeping pills Over-dose; Dependency Can really help patients 
fall asleep
Herbal medicines Not harmful; Lack of 
regulation
Unconvinced about any 
benefits; False claims
Cancer chemotherapy Risky treatment; Only 
hope for some people
Lifesaving for some; 
Many regret 
chemotherapy 
Insulin Few risks except with 
inappropriate use
Essential for patients 
with diabetes
Medicines for cholesterol 
(e.g. statins)
Various minor side effects 
(e.g. aches and pains)
Part of a wider solution 
(e.g. diet needed too); 
Unclear long-term 
benefits
Vitamin pills Not risky; Could be issues 
with over-use
Many people use them 
unnecessarily; Keeps 
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people generally 
healthy
Blood pressure medicines Low knowledge of risks; 
Assume there must be risks 
General comments
Flu vaccine Very mixed responses but 
generally low risk
Very mixed responses
In describing their perceptions, respondents construed ‘risks’ in different ways and 
inconsistently between items. One way that respondents construed ‘risks’ was as specific side 
effects with a given treatment. For example, respondents often associated ‘medicines to treat 
depression’ with risks of suicide, ‘medicines to treat erectile dysfunction’ with prolonged 
erections, and ‘X-rays’ with risks from repeated use (e.g. cancer) (Table 8). One respondent 
justified a 3/7 rating for the risks of erectile dysfunction medicines by noting: “I know that if 
erections last for more than…four hours is it? That can be a serious problem”. Another gave 
a 4/7 rating for the risks of medicines to treat depression: “There are some depression 
medicines out there that have some risk of suicide especially in adolescents”. 
A second way that respondents construed ‘risks’ was as the dangers of using a treatment 
inappropriately (Table 8). Sleeping pills were frequently associated with dependency: “There’s 
a risk of being dependent on them. People may not able to discontinue taking them” (4/7 risk 
rating). Insulin was associated with risks of improper administration: “I would say a four just 
because some people are not properly using insulin” (4/7). Several respondents also associated 
the risks of acupuncture with the skill of the acupuncturist: “It’s like a tattoo artist. The needles 
could go to the wrong place” (3/7). 
A third way that respondents construed ‘risks’ was broader than direct side effects and 
inappropriate use. The risks of antibiotics and prostate screening tests in particular were 
associated with such risks (Table 8). Antibiotics were often associated with patients not being 
able to have the treatment in the future and not being able to benefit from them (i.e. 
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antimicrobial resistance). These respondents rated the risks of antibiotics as higher than they 
would otherwise because there was a risk of future patients not being able to use them. One 
respondent’s comments reflected this construal: “The trouble is that [antibiotics] get over-
used” (4/7 risk rating). In a second example, prostate screening tests were associated with false 
positives leading to dangerous and unnecessary surgery. One respondent explained why they 
gave a 5/7 risk rating: “The risk from [prostate screening tests] is not the test itself but the data 
they develop leads people to do risky things when they didn’t need to. […]. Most men over a 
certain age have prostate cancer. […]. It leads to unnecessary surgeries because the data leads 
people to surgeries that don’t need”. 
Positive and negative experiences and feelings. The second main way that respondents justified 
their risk and benefit ratings was to explain their personal positive and negative experiences 
with different treatments. In so doing, respondents conveyed the ‘good’ and ‘bad’ feelings that 
they associated with different items or what is known as affect, defined here as: “the experience 
(with or without consciousness) of ‘goodness’ or ‘badness’ associated with external events and 
objects or internal representations (e.g. memories)” (p992)18.42 The role of affect in 
respondents’ risk and benefit ratings came across most clearly when strong positive and 
negative personal experiences were associated with a given item. 
On the one hand, many respondents provided examples of their positive experiences and hence 
feelings of ‘goodness’ associated with a treatment. Such feelings of goodness or positive affect 
particularly influenced respondents’ benefit ratings. One respondent explained how their 
positive experiences with erectile dysfunction medicines informed their high benefit rating 
(7/7): “Ohhhh. I think those can be very beneficial (laughs). I mean I take them! (laughs). Seven 
yup I’ll go for a seven on that one. Personal experience. They keep us old geezers active”. 
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Another respondent explained in detail how their positive experience with heart surgery led to 
a high benefit rating (6/7): “Heart surgery has been very beneficial for me. I would give it at 
least a six. […]. This medicine stuff is a miracle these days. If you think of all of the things that 
I’ve been through and I can [still] lead a normal life these days […]”. In a third example, a 
respondent justified their high benefit rating for blood pressure medicines (6/7): “They help 
me. I’ve had really high blood pressure forever, for 40 years, and [the medicine] doesn’t bring 
it down into the regular range but it brings it down by 50 and it makes a difference”. To be 
clear, respondents with positive associations to items may have very in-depth knowledge of 
the treatments from their own personal experience and therefore had ‘expert’ knowledge. 
However, what is interesting is the way they justified their answers. They conveyed their own 
positive experiences and they did not try to identify specific risks and benefits for the broader 
population. 
Respondents positive feelings about different treatments and subsequent ratings were also 
strongly influenced by family and friends. In many cases, risk and benefit ratings were justified 
by conveying how their spouses, sibling, parents, friends, and others experienced the treatment. 
One respondent considered the benefits of statins and gave a high benefit rating based on their 
husband’s experience (6/7): “I think it’s brought my husband’s down to an agreeable level”. 
This shows how again many respondents informed their benefit and risk ratings based on their 
own experiences and those of family and friends. One respondent attributed their high benefit 
rating (7/7) for the flu vaccine based on the experiences of their friends: “Well, I think it’s very 
beneficial. Everybody I know that has ever taken it hasn’t gone on to get the flu. The flu can 
spread easily and for older people it can be really dangerous. […]”. Another respondent gave 
a similar reason for giving a high benefit rating for their positive feelings about acupuncture 
(7/7): “Everyone I’ve ever heard did well and liked them. It’s not painful. It looks like it should 
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be but it’s not”. Respondents’ positive experiences with treatments and positive affect 
therefore had a clear influence on their risk and benefit ratings. 
While positive experiences often informed high benefit ratings, many respondents provided 
examples of their negative experiences with a treatment. In these cases, respondents expressed 
feelings of ‘badness’ about different treatments and judged the risks in particular to be high. 
One respondent explained their strong negative feelings towards cancer chemotherapy which 
led to a high-risk rating (6/7): “Oh gosh I’m scared to death of that. I’ve seen people go through 
it and they lose their hair, they get dry eyes. They get nausea. You need to be really sick to take 
those”. Another respondent explained why they gave X-rays a high-risk rating (5/7): “I know 
they were extremely careful with my husband [when he got multiple X-rays for cancer]. There’s 
been a lot in press that you shouldn’t do them as many”. In a third example, a respondent 
explained why they gave a high-risk rating for the flu vaccine (6/7): “Because I’ve seen lots of 
people having bad reactions. My sister-in-law just got horribly sick from hers. She just had it 
only a few weeks ago and she had a horrible rash on her arm, and she got very sick. I’m not 
crazy about the flu shot. I don’t want one if I don’t have to”. These negative feelings about 
different items was perhaps most strongly seen in one respondent’s justification for a high 
rating (6/7) for sleeping pills: “Because my grandmother died of sleeping pills. It was 
deliberate but still”. These examples illuminate how personal experiences and negative 
feelings associated with treatments strongly influenced respondents’ risk and benefit ratings.
 (4.) Discussion and Conclusion
The overriding goal of this pilot study was to generate experimental evidence that can inform 
future research comparing patients’ pharmaceutical benefit-risk perceptions across the adult 
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life span. In achieving this goal, the results shed light on major differences and similarities 
between older and younger adults.
(4.1) General perceptions of prescription medicines
Older versus younger adults were much more likely to associate prescription medicines to 
images of their benefits such as therapeutic effects and, to a lesser extent, financial expense. 
Older adults also were more likely to perceive prescription medicines as being effective and 
self-report experiencing a side effect in the past five years. In contrast, younger adults were 
much more likely to associate prescription medicines to images of abuse, dependency, and 
over-prescribing. 
One explanation for these age differences may well be that adults aged 58-93 years old use far 
more prescription medicines than adults aged 31-50.27,28,43 Kantor et al.43 found that 35% of 
US adults aged 20-39 years used at least one prescription medicine in 2011-2012 compared to 
65% aged 40-64 years and 90% aged 65 years and over. The official statistics body of the EU, 
Eurostat, reported similar patterns in 2014.27 In Ireland, 32% of adults aged 35-44 years self-
reported prescription medicine use in 2014 compared to 62% aged 55-64 years, 75% aged 65-
74 years and 87% aged 75 years and older.27 Polypharmacy also is much higher in older versus 
younger populations.28,43,44 Qato et al.28 found that more than one in three US adults 
concurrently used five or more prescription medicines in 2010-2011. Greater use may explain 
why older adults were more likely to associate prescription medicines with their benefits and 
financial expense, and younger adults to images of dependency, abuse and over-prescribing. 
While older adults have more to gain therapeutically and bear greater financial costs, younger 
adults have less to gain therapeutically and bear fewer financial costs. Great use also is 
accompanied by a high probability of experiencing side effects. 
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(4.2) Perceptions of past risk
The results show that the majority of both older and younger adults perceive greater risk today 
than 20 years ago for most items investigated ranging from diabetes and Alzheimer’s disease, 
to adults taking prescription medicines. This is consistent with previous nationally 
representative research.1,35,45 Interestingly, older adults were more likely to perceive greater 
risk today than their younger counterparts for every item except cancer and, to a lesser extent, 
heart disease. A fruitful area for research would be to verify these (pilot) results and understand 
why and for which risks older adults are more likely to perceive greater past risk. Such 
knowledge could help benefit-risk communicators understand how older versus younger adults 
are more or less sensitive in different hazard contexts. 
For prescription medicine risks specifically, both older and younger adults shared similar 
perceptions of past risk. Almost three quarters of all respondents perceived greater risk from 
‘adults taking prescription medicines’ with little difference between older and younger 
samples. This result initially appears to conflict with Slovic et al.1 who found that far fewer US 
adults perceived greater risk today from ‘prescription drugs’ (-37% difference). This 
discrepancy, however; may be because the present study specified ‘adults taking prescription 
medicines’ whereas Slovic et al.1 specified ‘prescription medicines’ more generally. This is 
supported by the finding that 38% of all respondents in the present study perceived more risk 
today than 20 years ago from ‘doctors making prescribing errors’. Respondents therefore were 
much more likely to perceive greater risk today from adults taking prescription medicines than 
doctors making prescribing errors (+36%). This emphasises the need for future risk perception 
studies to pay close attention to the specific referent of judgement when investigating 
pharmaceutical benefit-risk perceptions. 
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(4.3) Perceptions of patients and other actors
Other results further support the finding that both older and younger adults have particularly 
negative perceptions of the role of patients. Few respondents positively rated the ability of 
patients to take medicines safely and effectively. Rather, the patient’s role in taking 
prescription medicines was rated much more negatively than all other actors including 
regulatory agencies, pharmaceutical companies, prescribing doctors, and especially 
pharmacists. The majority of respondents also perceived ‘patients not following medication 
instructions’ and ‘patients receiving insufficient information’ as two of the most frequent 
causes of side effects. This general pattern supports past research with Slovic et al.1 finding the 
same ordering and similar values. Other nationally representative studies also consistently 
show that adults in the United States and Europe are more likely to trust their pharmacist than 
almost any other actor and view them as a key source of benefit-risk information.46-47 
Curiously, older versus younger adults were much more likely to rate prescribing doctors as 
excellent or good (+35% difference). The authors are unaware of any studies identifying 
substantial differences between how older and younger adults perceive the ability of their 
doctors. On the one hand, this finding may be an erroneous outlier. The study had a 
convenience sample and there is no clear evidence of nationally representative research 
identifying such an age-related difference. On the other hand, few studies have reported age-
related results on how older versus younger respondents perceive the ability of prescribing 
doctors. Understanding whether these results are spurious or accurate could be tested in 
nationally representative surveys. If a significant difference between older versus younger 
perceptions of prescribing doctors is supported, there will be important implications for 
benefit-risk communication. 
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 (4.3) Justifying Benefit-Risk Ratings 
When analysing older and younger respondents’ benefit-risk ratings, a familiar pattern was 
found. Most medicines, medical procedures and tests were rated as high-benefit and low-risk. 
Some items – vitamin pills, Alzheimer’s medicines, herbal medicines, acupuncture – were 
perceived as lower in benefit than the majority of pharmaceutical items. A few other items – 
cancer chemotherapy, heart surgery, sleeping pills, depression medicines – were rated as 
higher-risk that all other medical items. In contrast, most non-medical items ranging from 
cigarette smoking to nuclear power plants and genetically modified food, were perceived as 
low-benefit and high-risk. This pattern and clustering of medical and non-medical items is 
highly consistent with past studies including those conducted with nationally representative 
samples.1,21,48 They also support recent findings that patterns of public risk perceptions remain 
“practically unchanged” since they were first investigated in the late 1970s, albeit with a few 
notable exceptions.49 
Interestingly, older respondents were more likely than their younger counterparts to perceive 
lower risk for over three quarters of medical and non-medical items surveyed. While little 
research has been conducted in the pharmaceutical domain, past studies conducted in other 
contexts support these results by showing that older versus younger adults perceive lower risk 
for a wide variety hazards.20,50,51 Greenberg20, for example, surveyed the environmental risk 
perceptions of US adults aged 75 years old and over. Older versus younger adults were less 
concerned about almost every environmental risk examined including water quality, open 
space, traffic congestion and other chronic issues.20 In contrast, older adults’ risk perceptions 
were much closer to those of their younger counterparts for acute risk issues such as nuclear 
facility failures and natural hazard events.20 However, other studies have found the opposite 
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effect with older versus younger adults perceiving greater risk.52-54 Siegrist et al.54, for 
example, found that older versus younger adults perceived significantly greater risk for various 
technological, social and natural hazards. The wide variation in empirical findings examining 
whether older versus younger adults perceive greater risk or not suggests that a more 
sophisticated approach is needed. In particular, understanding which age groups perceive more 
or less risk in general may be a Sisyphean task. A more fruitful line of inquiry, as this study 
suggests, would be to understand under which conditions, and for which hazards, older versus 
younger adults perceive more or less risk.
Beyond comparing benefit-risk perceptions, a key aim of this study was to explore, 
qualitatively, how older adults justified their quantitative benefit-risk ratings (section 3.7). 
When justifying their ratings, older adults construed ‘risk’ in at least three main ways: (1) as 
side effects, (2) as dangers of improper use, and (3) as wider issues. This variation strongly 
questions whether general measures of benefit-risk perceptions can be used in future studies to 
identify age-related differences. For example, one respondent rated the risks of sleeping pills 
by considering the risks of dependency (improper use). To what extent can this respondent’s 
rating be compared with that of another who, quite reasonably, only considered side effects 
such as ‘patients being drowsy the following morning’? Would the second respondent have 
changed their rating if they believed that improper use was an acceptable consideration in their 
quantitative risk judgement? The results therefore show that future study designs, and 
especially those examining age-related differences, need to distinguish clearly between 
different construes of risk (and benefit). 
A second key finding was that older adults’ personal experiences had a strong influence on 
their pharmaceutical benefit-risk perceptions. Treatments that were associated with 
Page 28 of 42
http://mc.manuscriptcentral.com/tirs
Therapeutic Innovation & Regulatory Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
29
positive/negative experiences and feelings of ‘goodness’/’badness’ strongly influenced 
respondents’ benefit-risk ratings. While positive experiences/affect were associated with high 
benefit ratings, negative experiences/affect were associated with high risk ratings. A major 
body of risk perception research has emphasised the importance of affect (and emotion) on 
perceptions of risk (and benefit).42,55,56 To be clear, this is not to say that emotion and affect 
determine older adults’ benefit-risk decisions. Rather, older adults’ judgements and decisions 
were influenced by the negative/positive feelings they associated with different treatments. 
This is an important distinction as, in real-world contexts, prescription medicine decisions are 
not made in a vacuum. As McNutt31 explains: “Physicians should ensure that the information 
used in the patient’s decision making is reasonable for the individual patient and that the patient 
understands the ramifications of choice. The physician should be a navigator, not a pilot”. 
 
The strong influence of ‘risk as feelings’ provide support for Slovic et al.’s1 suggestion that a 
high negative correlation between pharmaceutical benefit and risk is due to a “reliance on the 
affect heuristic”. Moreover, the present study provides a rich understanding and description of 
the influence of affect for various medical treatments. Older adults also were clearly influenced 
by their personal experiences and those of close family and friends. However, the study did not 
provide evidence as to whether older adults were more likely to rely on affective processes 
than their younger counterparts or not. This presents an important line of inquiry for future 
research. In particular, psychological judgement and decision-making studies, conducted 
primarily in nonpharmaceutical contexts, have consistently found that older versus younger 
adults rely more heavily on affective processes.17,18,56 The results of this study provide strong 
evidence that understanding age-related differences in affective processes would be a fruitful 
area for future research.
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0% 20% 40% 60% 80% 100%
Wrongly filled by pharmacist
Hospital mistake when filling prescription
Doctor prescribed wrong dosage
Lack of government regulating medicine
Patient health plan restricted access to safer medicine
Patient unusually sensitive to the medicine
Insufficient information to patient
Patient did not follow instructions
Always, Very Often, Often Occasionally Rarely Never
Figure 1: Bar chart showing how often all respondents (N=80) think side effects are caused by various explanations.
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Table 1: Demographic and health information for older and younger samples
Older Sample Younger Sample
Dates Nov. 1st – 10th, 2017 Feb 1st – 14th, 2018
Sample size 40 40
Age Range 58 to 93 31 to 50
Mean Age 72 39
Male 44% 45%
Education (%) Some schooling complete/ No high school diploma 23% 0%
High School Graduate or 
Equivalent 18% 30%
Bachelor’s Degree 21% 50%
Master’s Degree 36% 20%
Professional/ Doctorate 
Degree 3% 0%
Employment (%) Working Full-Time 13% 45%
Working Part-Time 23% 25%
Retired 64% 3%
Full Time Homemaker 0% 5%
Unemployed (looking for 
work) 0% 8%
Student 0% 10%
Other 0% 5%
Do you currently 
have a doctor? 
(%)
Yes 97% 60%
Do you currently 
smoke? (%) Yes 0% 35%
Table 2: Sixteen hazard items
Air travel Heart disease
Adults getting Alzheimer’s disease Hurricanes
Cancer Adults getting HIV/AIDS
Climate change Nuclear power
Diabetes Pesticides
Driving a car Adults taking prescription medicines
Doctors making prescribing errors Train travel
Flooding Chemicals
Box 1: Psychometric risk and benefit questions
Risks of medical technologies (to those exposed). To what extent would you say that adults who are taking or 
undergoing this medical treatment are at risk1 of experiencing personal harm from it? (1 = they are not at risk; 
7 = they are very much at risk)
Benefits of medical technologies. In general, how beneficial do you consider this treatment to be? (1 = not at 
all beneficial; 7 = very beneficial)
Risks of non-medical technologies (to those exposed). To what extent would you say that adults who are 
exposed to the following are at risk2 of experiencing personal harm from it? (1 = they are not at risk; 7 = they 
are very much at risk)
Benefits of non-medical technologies. In general, how beneficial do you consider the following items to be for 
those exposed to it? (1 = not at all beneficial; 7 = very beneficial)
Table 3: Medical and non-medical items surveyed
Medicines Medical Procedures & Tests Non-Medical Technologies
1 ‘Risk’ was intentionally not defined. Respondents were left to interpret what ‘risk’ meant for each technology.  
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Medicine to treat depression Heart surgery Cell phones
Medicines to slow the progression 
of Alzheimer’s disease
Medical x-rays Nuclear power plants
Medicines to treat erectile 
dysfunction
Prostate screening tests Pesticides
Antibiotics Acupuncture Cigarette smoking
Sleeping pills High-fat foods
Herbal medicines Genetically modified food
Cancer chemotherapy Automobiles
Insulin Alcoholic beverages
Medicines for cholesterol (e.g. 
statins)
Coffee
Vitamin pills Air travel
Blood pressure medicines
MMR vaccine
Flu vaccine
Allergy medicines
Table 4: Spontaneous imagery associated to “Prescription Medicines”
Older (%) Younger (%) All (%)
Helpful/Beneficial/Good 24 7 11
HCPs (e.g. "My Doctor") 14 16 15
Types of Disease and Illness 12 11 11
Expensive 10 2 6
Names of Specific Drugs 9 9 9
Side Effects 8 7 7
Own and Family Prescription Medicines 6 3 5
Dependency/Abuse/Over-Prescribing 5 15 10
Annoying/Want to Avoid if Possible 4 5 5
Industry Profits 2 4 3
General Safety 1 5 3
Other (e.g. Packaging) 7 15 14
No. of Responses 93 (count) 94 (count) 187 (count)
Table 5: Percentage of all respondents (N=80) for the question: ‘Do you think there is more, less, or about the 
same risk today than 20 years ago for the following items?’ 
More Less About the Same
Climate Change 94 3 4
Diabetes 78 11 11
Flooding 76 6 18
Adults Taking Prescription Medicines 74 13 14
Hurricanes 71 4 25
Cancer 69 11 19
Chemicals 69 16 15
Adults Getting Alzheimer’s Disease 65 8 26
Heart Disease 65 11 24
Pesticides 63 24 14
Driving a Car 53 29 19
Nuclear Power 50 23 28
Doctors Making Prescription Errors 48 21 30
Adults Getting HIV 35 53 10
Air Travel 34 50 16
Train Travel 19 46 35
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Table 6: Table showing the percentage (%) of older and younger group respondents that rated five actors as either 
excellent or good in making sure that prescription medicines are safe and effective. 
Older (%) Younger (%) All (%)
Pharmacists 80 70 75
Prescribing Doctors 73 38 55
Pharma Companies 50 40 45
Regulatory Agencies 48 38 43
Patients 33 23 28
Table 7: Respondents perceptions of effectiveness and side effects. Effectiveness: “How often do you believe that 
prescription medicines work as intended for patients?” Side Effects: “How often do you believe that patients 
experience unwanted effects or side effects from prescription medicines?” 
Effectiveness Side Effects
Older (%) Younger (%) All (%) Older (%) Younger (%) All (%)
Always 0 3 1 3 10 6
Very Often 43 20 31 20 18 19
Often 58 55 56 43 30 36
Occasionally 0 23 11 30 33 31
Rarely or Never 0 0 0 5 10 8
Table 8: Older respondents’ (N=40) most common risk and benefit associations for all pharmaceutical items.
Item Risks Benefits
Medicines to treat 
depression
Suicide; over-dose; 
incorrect use
Benefits vary between 
patients; Patients need 
appropriate medicines 
Medicines to treat 
Alzheimer’s Disease
Low knowledge of any 
risks
Low knowledge of any 
benefits
Medicines to treat erectile 
dysfunction
Most unaware of any risks; 
Prolonged erections 
Very effective for those 
who need them
Antibiotics Antimicrobial resistance 
and over-use
Antimicrobial 
resistance reduces 
benefits
Sleeping pills Over-dose; Dependency Can really help patients 
fall asleep
Herbal medicines Not harmful; Lack of 
regulation
Unconvinced about any 
benefits; False claims
Cancer chemotherapy Risky treatment; Only 
hope for some people
Lifesaving for some; 
Many regret 
chemotherapy 
Insulin Few risks except with 
inappropriate use
Essential for patients 
with diabetes
Medicines for cholesterol 
(e.g. statins)
Various minor side effects 
(e.g. aches and pains)
Part of a wider solution 
(e.g. diet needed too); 
Unclear long-term 
benefits
Vitamin pills Not risky; Could be issues 
with over-use
Many people use them 
unnecessarily; Keeps 
people generally 
healthy
Blood pressure medicines Low knowledge of risks; 
Assume there must be risks 
General comments
Flu vaccine Very mixed responses but 
generally low risk
Very mixed responses
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Allergy medicines No clear risks except over-
doses
Helpful for people with 
allergies 
Heart surgery Any surgery comes with 
risk; Heart surgery has a 
serious risk of death
Heart surgery is 
essential if you need it
X-rays Risks from repeated use 
(e.g. cancer)
A necessity
Prostate screening tests Little risk from the actual 
test; Serious side effects 
with false positive
Beneficial and 
lifesaving when tests 
are accurate
Acupuncture Generally harmless; 
Requires a safe 
acupuncturist 
Can reduce pain but 
unclear why; Worth 
trying
Page 42 of 42
http://mc.manuscriptcentral.com/tirs
Therapeutic Innovation & Regulatory Science
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
